论文部分内容阅读
目的探讨抗CD105、CD34抗体标记的肿瘤微血管密度(microvascular density,MVD)在肝细胞肝癌(hepatocellular carcinoma,HCC)中的表达及其判断HCC肝移植(liver transplantation,LT)术后肿瘤复发的临床应用价值。方法收集2001年1月至2006年12月期间获得随访资料的112例HCC肝移植患者为研究对象,应用免疫组织化学方法检测112例(其中伴有癌旁组织为100例)HCC肝移植患者肿瘤组织中微血管CD105、CD34的表达,分析其与肝移植术后复发的相关性并与临床病理指标进行比较。结果 CD34主要表达于HCC的肿瘤区域,显示瘤内成熟肿瘤血管,而CD105主要表达于紧邻肿瘤的癌旁区域,能够显示癌旁活性新生血管;pTNM分期、肿瘤直径及甲胎蛋白(AFP)值仅在单因素分析中对预测肝移植复发有统计学意义(P<0.05),癌旁MVD-CD105和门静脉癌栓(portal veintumor thrombus,PVTT)在单因素及多因素分析中均显示对预测肝移植复发有统计学意义(P<0.05),并且癌旁MVD-CD105与门静脉癌栓(rs=0.257,P=0.010)、pTNM分期(rs=0.350,P=0.000)、AFP(rs=0.208,P=0.038)具有相关性。结论抗CD105抗体可作为标记肝癌内活性新生血管的理想标记物,MVD-CD105在HCC癌旁组织中的表达可作为HCC肝移植术后预测复发的一项独立指标,有前景成为辅助HCC肝移植术后进一步治疗的标记物。
Objective To investigate the expression of anti-CD105 and CD34 antibody-labeled tumor microvessel density (MVD) in hepatocellular carcinoma (HCC) and its clinical application in determining tumor recurrence after HCC liver transplantation (LT) value. Methods A total of 112 HCC patients who received follow-up data from January 2001 to December 2006 were enrolled in this study. Immunohistochemistry was used to detect the expression of tumor in 112 patients with paraneoplastic tissues of 100 patients with HCC The expression of CD105 and CD34 in microvessels was analyzed. The correlation between the expression of CD105 and CD34 in liver tissues and the recurrence after liver transplantation was analyzed and compared with the clinicopathological parameters. Results CD34 was mainly expressed in the tumor region of HCC and showed mature tumor vessels in the tumor. CD105 was mainly expressed in the paracancer adjacent to the tumor and could show paracancerous viable neovascularization. The pTNM stage, tumor diameter and AFP value Predict the recurrence of liver transplantation only in univariate analysis was statistically significant (P <0.05), adjacent to the MVD-CD105 and portal vein tumor thrombus (PVTT) in univariate and multivariate analysis showed that the prediction of liver There was a significant difference between the two groups (P <0.05). The number of MVD-CD105 in adjacent tumor and portal vein tumor thrombus (rs = 0.257, P = 0.010) P = 0.038). Conclusion The anti-CD105 antibody can be used as an ideal marker for detecting active neovascularization in HCC. The expression of MVD-CD105 in HCC tissues can be used as an independent index to predict the recurrence of HCC after liver transplantation. Postoperative further treatment of the marker.